Top Industry News

Eli Lilly and Company has announced an additional $4.5-billion investment across two of its three sites in Lebanon, Indiana, which brings the company’s total Indiana capital expansion commitments since 2020 to more than $21 billion.   The investment…

Amgen has announced plans to invest an additional $300 million in its biologics manufacturing facility in Juncos, Puerto Rico, following up on its earlier $650-million investment in the same facility, which was announced in September 2025. …

Merck & Co. has completed its $5.3-billion acquisition of Terns Pharmaceuticals, a clinical-stage bio/pharmaceutical company focused on oncology.  The deal was announced in March 2026.  Terns’ lead candidate, TERN-701, is an investigational oral drug for treating chronic phase…

Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg, a private equity firm, for approximately $1.075 billion, consisting of cash and a $50-million seller note. The microbiology…

The latest from CDMOs, CMOs, and suppliers featuring Alcami, Mikart, PharmaLogic, Ecolab, LTS, Ardena and Symeres.   Chemicals/Chemical API Manufacturing * PharmaLogic Opens New Radiopharmaceutical Mfg Facility Biologics Manufacturing * Ecolab Opens New Bioprocessing Lab Formulation Development/Drug Product Manufacturing * Mikart Opens New HQ, Expanding Mfg * LTS…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Novartis, Bayer, GSK, UCB, Sanofi, BioNTech, and Angelini Pharma. Highlights below.   For the latest news roundup on small and Emerging Pharma companies, see…

The latest from small and Emerging Pharma companies featuring Esperion, Madrigal, Arrowhead, CellCentric, Windward Bio, and Tris Pharma.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Archimed To Acquire Esperion for…

In one of the largest deals thus far in 2026, Sun Pharmaceutical Industries, a Mumbai, India-based bio/pharmaceutical company, has agreed to acquire Organon & Co., the former women’s health, biosimilars, and established brand business of…

Gilead Sciences has completed its $7.8-billion acquisition of Arcellx, a bio/pharmaceutical company focused on oncology. The deal was announced in February (February 2026).  Kite, a subsidiary of Gilead Sciences, and Arcellx had an existing collaboration to co-develop and co-commercialize Arcellx’s lead…

Eli Lilly and Company has agreed to acquire Ajax Therapeutics, a bio/pharmaceutical company developing JAK inhibitors for treating myeloproliferative neoplasms, a group of rare, chronic blood cancers, for $2.3 billion.  JAK inhibitors are a class of targeted…